Literature DB >> 18503169

Serum zinc and albumin levels in pulmonary tuberculosis patients with and without HIV.

Kuppamuthu Ramakrishnan1, Rajaiah Shenbagarathai, Karuppusamy Kavitha, Alagappa Uma, Ramakrishnan Balasubramaniam, Ponniah Thirumalaikolundusubramanian.   

Abstract

Limited data are available on the relationship between nutritional status and pulmonary tuberculosis (PTB). Zinc plays a vital role in the immune status of the individual. The present study was carried out to estimate serum zinc and albumin levels in newly detected adult active PTB patients with (n = 20) and without (n = 20) HIV, and to compare them with the levels in controls (healthy family members; n = 20) who satisfied rigid selection criteria. Standard methods were adopted to collect an early morning fasting blood sample for zinc (by Atomic Absorption Spectrometer) and albumin (estimated by the bromocresol green method). The mean +/- SD for BMI, zinc and albumin among the controls, HIV positive and HIV negative patients were 19.6 +/- 0.6, 18 +/- 0.4 and 18.5 +/- 0.6 kg/m(2); 117.13 +/- 4.2, 53.9 +/- 8 and 65.5 +/- 9.8 microg/dL; and 4.1 +/- 0.6, 2.9 +/- 0.4 and 3.6 +/- 0.7 g/dL, respectively. All three parameters were significantly low in active PTB patients irrespective of HIV status, but more so in HIV-positive individuals. These changes may be attributable to nutritional factors, enteropathy and acute phase reactant proteins. Hence, the National AIDS Control Organization (NACO) in India is providing nutritional supplements to those HIV-infected cases inducted for antiretroviral therapy and nutritional counseling for others as a part of a national policy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18503169

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  12 in total

1.  Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anneke C Hesseling; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Tjokosela Tikiso; Lubbe Wiesner; Mine de Kock; Jana Winckler; Jennifer Norman; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.

Authors:  Eric F Egelund; Marc Weiner; Rajendra P Singh; Thomas J Prihoda; Jonathon A L Gelfond; Hartmut Derendorf; William R Mac Kenzie; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

3.  Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.

Authors:  Elin M Svensson; Kelly E Dooley; Mats O Karlsson
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

4.  Investigation of Zinc Supplement Impact on the Serum Biochemical Parameters in Pulmonary Tuberculosis: A Double Blinded Placebo Control Trial.

Authors:  Bahareh Zolfaghari; Mahboobeh Ghanbari; Hadis Musavi; Parizad Bavandpour Baghshahi; Mohammad Taghikhani; Fatemeh Pourfallah
Journal:  Rep Biochem Mol Biol       Date:  2021-07

5.  Up-regulation of Slc39A2(Zip2) mRNA in peripheral blood mononuclear cells from patients with pulmonary tuberculosis.

Authors:  Yan-ting Tao; Qing Huang; Ya-li Jiang; Xiao-lei Wang; Ping Sun; Yuanyuan Tian; Hai-liang Wu; Min Zhang; Si-bo Meng; Yu-shu Wang; Qing Sun; Lian-ying Zhang
Journal:  Mol Biol Rep       Date:  2013-05-18       Impact factor: 2.316

6.  Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.

Authors:  Elin M Svensson; Francesca Aweeka; Jeong-Gun Park; Florence Marzan; Kelly E Dooley; Mats O Karlsson
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

7.  Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.

Authors:  Elin M Svensson; Stephen Murray; Mats O Karlsson; Kelly E Dooley
Journal:  J Antimicrob Chemother       Date:  2014-12-21       Impact factor: 5.790

8.  Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin.

Authors:  E M Svensson; A-G Dosne; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-11-08

9.  Essential and toxic metals in serum of individuals with active pulmonary tuberculosis in an endemic region.

Authors:  Zahra Sepehri; Nima Mirzaei; Aliyeh Sargazi; Alireza Sargazi; Abolfazl Panahi Mishkar; Zohre Kiani; Hamid Owaysee Oskoee; Donya Arefi; Saeid Ghavami
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2017-01-23

10.  Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations.

Authors:  Muhammad F Rasool; Sundus Khalid; Abdul Majeed; Hamid Saeed; Imran Imran; Mohamed Mohany; Salim S Al-Rejaie; Faleh Alqahtani
Journal:  Pharmaceutics       Date:  2019-11-05       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.